Dabrafenib Plus Trametinib in Patients With BRAF V600E–Mutant Anaplastic Thyroid Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
Ann. Oncol 2022 Jan 10;[EPub Ahead of Print], V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho, JHM Schellens, JC Soria, PY Wen, CC Zielinski, ME Cabanillas, A Boran, I Palanichamy, P Burgess, T Romero Salas, B KeamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.